Cannabis medicinal na lesão medular: aplicabilidade e considerações práticas
DOI:
https://doi.org/10.11606/issn.2317-0190.v31iSupl.1a225006Palavras-chave:
Síndrome Medular Central, Cannabis, Reabilitação, Dor, Espasticidade MuscularResumo
Lesões da medula espinhal (LME) são uma prioridade de saúde global. Na população com LME, estima-se que 65-78% dos indivíduos relatam sintomas de espasticidade, no primeiro ano após a lesão. Até 80% das pessoas com LME sentirão dor neuropática. A ineficiência do modelo de tratamento atual levou as pessoas com LME a explorar métodos alternativos, como o uso da Cannabis medicinal (CM), para controlar as complicações.
Downloads
Referências
Barbiellini Amidei C, Salmaso L, Bellio S, Saia M. Epidemiology of traumatic spinal cord injury: a large population-based study. Spinal Cord. 2022;60(9):812-819. Doi: https://doi.org/10.1038/s41393-022-00795-w
Stillman M, Mallow M, Ransom T, Gustafson K, Bell A, Graves D. Attitudes toward and knowledge of medical cannabis among individuals with spinal cord injury. Spinal Cord Ser Cases. 2019;5:6. Doi: https://doi.org/10.1038/s41394-019-0151-6
Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl 1):S45-S66. Doi: https://doi.org/10.1097/j.pain.0000000000001929
Nabata KJ, Tse EK, Nightingale TE, Lee AHX, Eng JJ, Querée M, et al. The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review. Curr Neuropharmacol. 2021;19(3):402-432. Doi: https://doi.org/10.2174/1570159X18666200420085712
Petrosino S, Palazzo E, Novellis V, Bisogno T, Rossi F, Maione S, et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology. 2007;52(2):415-22. Doi: https://doi.org/10.1016/j.neuropharm.2006.08.011
Petzke F, Tölle T, Fitzcharles MA, Häuser W. Cannabis- Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. CNS Drugs. 2022;36(1):31-44. Doi: https://doi.org/10.1007/s40263-021-00879-w
Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182. Doi: https://doi.org/10.1002/14651858.CD012182.pub2
Zettl UK, Rommer P, Hipp P, Patejdl R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord. 2016;9(1):9-30. Doi: https://doi.org/10.1177/1756285615612659
Wilsey B, Marcotte TD, Deutsch R, Zhao H, Prasad H, Phan A. An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease. J Pain. 2016;17(9):982-1000. Doi: https://doi.org/10.1016/j.jpain.2016.05.010
Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, et al. Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology. 2017;42(9):1752-1765. Doi: https://doi.org/10.1038/npp.2017.51
MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12-19. Doi: https://doi.org/10.1016/j.ejim.2018.01.004
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2024 Acta Fisiátrica
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
